ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Organon, Daiichi Sankyo and Yuhan side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Organon×Daiichi Sankyo×Yuhan×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

OrganonDaiichi SankyoYuhan
studies on the registry514499174
open to participants now03735
phase 3 studies under way1215
reach primary completion within a year11110
programswith a study of their own in two years12053

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOrganonDaiichi SankyoYuhan
Phase 100%

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%

Yuhan: 45 of its 53 programs at phase 1

  1. AD-1161phase 1
  2. AD-116Aphase 1
  3. AD-118phase 1
  4. AD-230phase 1
  5. PA-111phase 1

and 40 more — sign in to see them all

85%
Phase 200%25%

Yuhan: 3 of its 53 programs at phase 2

  1. AD-211phase 2
  2. lesigerceptphase 2
  3. YH32364phase 2
6%
Phase 300%

Daiichi Sankyo: 4 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. raludotatug deruxtecanphase 3
20%

Yuhan: 5 of its 53 programs at phase 3

  1. AD-227Bphase 3
  2. AD-233Aphase 3
  3. AD-233Bphase 3
  4. AD-2282phase 3
  5. YHP2401phase 3
9%
Approved, new studies

Organon: 1 of its 1 programs at approved, new studies

  1. tapinarofapproved, new study
100%

Daiichi Sankyo: 4 of its 20 programs at approved, new studies

  1. quizartinibapproved, new study
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study
20%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Organon1 readouts · 1 phase 3·········

Organon, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tapinarofapproved, new study · Aug 0 · NCT07265479
··
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibapproved, new study · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
Yuhan10 readouts · 0 phase 3

Yuhan, Nov ’26: 3 programs whose next study reaches primary completion

  1. AD-234phase 1 · Nov 0 · NCT07717775
  2. AD-2341phase 1 · Nov 0 · NCT07717775
  3. AD-2342phase 1 · Nov 0 · NCT07717775
·

Yuhan, Jan ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Bphase 1 · Jan 26 · NCT07912840
  2. YHR2602phase 1 · Jan 26 · NCT07912840

Yuhan, Feb ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Aphase 1 · Feb 2 · NCT07912827
  2. YHR2601phase 1 · Feb 2 · NCT07912827

Yuhan, Mar ’27: 1 program whose next study reaches primary completion

  1. AD-211phase 2 · Mar 0 · NCT07550231
··

Yuhan, Jun ’27: 2 programs whose next study reaches primary completion

  1. YH32364phase 2 · Jun 0 · NCT06975410
  2. lesigerceptphase 2 · Jun 19 · NCT07415551
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Organon

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 0

None

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Yuhan

New programs 6

  • YHP2508Aphase 1 · first study · Oct 28
  • YHP2508Bphase 1 · first study · Oct 28
  • YHR2601phase 1 · first study · Oct 28
  • YHR2602phase 1 · first study · Oct 28
  • AD-233Aphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2
  • AD-233Bphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionOrganonDaiichi SankyoYuhan
Dyslipidemias2 of 3 · compare here–

Daiichi Sankyo in Dyslipidemias: 3 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Dyslipidemias in search

Yuhan in Dyslipidemias: 5 programs

  1. PA-111phase 1
  2. AD-117phase 1
  3. AD-117Aphase 1
  4. AD-231phase 1
  5. PA-111Aphase 1

Their studies: Yuhan’s studies of Dyslipidemias in search

Hypertension2 of 3 · compare here–

Daiichi Sankyo in Hypertension: 2 programs

  1. rosuvastatinphase 1
  2. Ezetimibeapproved, new study

Their studies: Daiichi Sankyo’s studies of Hypertension in search

Hyperlipidemias2 of 3 · compare here–

Daiichi Sankyo in Hyperlipidemias: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hyperlipidemias in search

Yuhan in Hyperlipidemias: 2 programs

  1. Treatment A(AD-236A)phase 1
  2. Treatment B(AD-236B)phase 1

Their studies: Yuhan’s studies of Hyperlipidemias in search

Hypercholesterolemia2 of 3 · compare here–

Daiichi Sankyo in Hypercholesterolemia: 4 programs

  1. rosuvastatinphase 1
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Hypercholesterolemia in search

Yuhan in Hypercholesterolemia: 1 program

  1. AD-2282phase 3

Their studies: Yuhan’s studies of Hypercholesterolemia in search

Neoplasm Metastasis2 of 3 · compare here–

Yuhan in Neoplasm Metastasis: 1 program

  1. YH32364phase 2

Their studies: Yuhan’s studies of Neoplasm Metastasis in search

Diabetes Mellitus, Type 22 of 3 · compare here–

Daiichi Sankyo in Diabetes Mellitus, Type 2: 1 program

  1. Atorvastatinapproved, new study

Their studies: Daiichi Sankyo’s studies of Diabetes Mellitus, Type 2 in search

Yuhan in Diabetes Mellitus, Type 2: 2 programs

  1. AD-233Aphase 3
  2. AD-233Bphase 3

Their studies: Yuhan’s studies of Diabetes Mellitus, Type 2 in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Organon 1 of 1 · Daiichi Sankyo 14 of 20 · Yuhan 1 of 53 programs (13 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.